# Bristol Myers Squibb surpassed Wall Street expectations in the first quarter.

*biotech · news · 2026-04-30 · Devdiscourse*

## Key points

- Bristol Myers Squibb's Q1 adjusted earnings were $1.58 per share, exceeding Wall Street forecasts.
- Eliquis sales rose 16% year-over-year to $4.14 billion, surpassing 75% new prescription share.
- The company's total quarterly revenue hit $11.49 billion, beating analysts' expectations of $10.9 billion.
- Bristol Myers' growth segment increased 12% to $6.23 billion, now over half of total revenue.

**Companies:** Bristol Myers Squibb, Pfizer

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/headlines/3891981-bristol-myers-squibb-soars-with-strong-eliquis-and-cancer-drug-sales)

---

Canonical: https://newsio.io/n/dfab9cd6-d323-4126-b21b-ac30b9b78379/bristol-myers-squibb-surpassed-wall-street-expectations-in-the-first-quarter-the
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works